Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Union of South American Nations (UNASUR) proposes centralised purchase of hepatitis C treatments Olysio and Sovaldi for member states

Regional agency UNASUR is aiming to secure price discounts on Sovaldi (sofosbuvir; Gilead Sciences, US) and Olysio (simeprevir; Janssen-Cilag, US), generating savings and reducing the risk of compulsory licences or price cuts.

Published
4 hours ago
From
IHS
Is There Any Good Reason Left to Delay Hepatitis C Treatment?

Physicians increasingly argue that the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait for treatment?

Published
17 April 2015
From
Poz
Cepheid announces European approval of Xpert HCV Viral Load

Quantitative test for rapid measurement of hepatitis C virus viral load and confirmation of HCV infection delivers on-demand results in less than 2 hours.

Published
16 April 2015
From
Cepheid press release
Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

Published
09 April 2015
From
The Street
Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations

Merck today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic HCV genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis.

Published
09 April 2015
From
Merck press release
At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

Published today in the journal Science Translational Medicine, researchers from the National Institutes of Health (NIH) reported chlorcyclizine prevented hepatitis C infection in a petri dish and in humanized mice. They said it was effective and did and did not produce any significant cell toxicity when given along with existing drugs to treat hepatitis C.

Published
09 April 2015
From
Healthline
Abstracts Have Been Posted: International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Abstracts for The International Liver Congress™ 2015 for the 50th annual meeting of the European Association for the Study of the Liver (EASL) are now available.

Published
09 April 2015
From
HCV New Drugs Research
WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine

The World Health Organization has issued a guidance document on the design of bioequivalence studies for a leading hepatitis C medicine. Generic drug companies seeking prequalification by the WHO need to demonstrate that their generic version is equivalent to the originator drug.

Published
08 April 2015
From
Intellectual Property Watch
Alert: Serbia is losing harm reduction

The situation with harm reduction in Serbia is getting increasingly alarming after withdrawal of the Global Fund. Three organizations doing HR programs in Serbia for more than a decade are struggling to maintain services. We want a different future for their beneficiaries. ""Please use your communication with donors to put Serbia back as eligible for funding the harm reduction programs - we keep knocking on closed doors. The EU is the biggest donor here and has no health programs whatsoever; as for other donors, we are ineligible whomever we approach, and keep losing on relevance to the calls,“ says Miodrag Atanasjevic, NGO Veza, Belgrade, Serbia.

Published
02 April 2015
From
Eurasian Harm Reduction Network
Cannabis use reduces risk of insulin resistance in people with HIV/HCV co-infection

Cannabis use is associated with a reduced risk of insulin resistance in people with HIV and hepatitis C virus (HCV) co-infection, French investigators report in the online

Published
02 April 2015
By
Michael Carter
← First12345...121Next →

Filter by country